Questions over ghostwriting in drug industry

Analysis claims papers drafted by medical writers downplayed risks of hormone replacement therapy.


Nature













Share on Tumblr

Questions over ghostwriting in drug industry

Questions over ghostwriting in drug industry Image:

By Ewen Callaway

Journal articles on hormone replacement therapy (HRT) ghostwritten by medical writers employed by the pharmaceutical industry serially understated the treatment's risks and promoted unapproved uses, according to an analysis of industry documents.

The analysis, published September 7 in the journal PLoS Medicine, is based on some 1,500 e-mails, contracts and other documents made public in July 2009, after The New York Times and PLoS Medicine successfully argued that their release would be in the public interest. Many thousands more papers remain sealed as part of ongoing lawsuits brought by more than 14,000 women against the drug maker Wyeth, which was bought last year by the pharmaceutical giant Pfizer, based in New York.

"People needed to know about what was going on behind closed doors in terms of these articles," says Adriane Fugh-Berman, a researcher at Georgetown University Medical Center in Washington DC, who conducted the analysis. She is a paid expert witness for plaintiffs against Wyeth and Pfizer.

Millions of women took a mix of the hormones oestrogen and progesterone called Prempro. HRT was intended to ease the symptoms of menopause, but many studies suggested that it also helped to protect against heart disease, osteoporosis and other conditions.

But a landmark 2002 study of tens of thousands of women enrolled in the Women's Health Initiative clinical trial found that HRT did not prevent heart disease, and increased the risk of breast cancer and stroke. Breast cancer rates in the United States have since fallen as many women abandoned HRT, although it is still prescribed to combat severe symptoms of menopause such as hot flushes.

Literary haunts

Fugh-Berman's study focuses on Wyeth's previously disclosed use of ghostwriters on papers discussing Prempro. The documents detail arrangements made between Wyeth, DesignWrite--the company it employed to pen articles on HRT, based in Princeton, New Jersey--and the academic authors named on papers.

Between 1997 and 2003, DesignWrite oversaw the publication of dozens of peer-reviewed articles, conference abstracts and posters on HRT, receiving up to $25,000 per project. The documents suggest a deep involvement in writing, editing and overseeing the publication of the papers, with sometimes only minimal involvement from the named authors.

"The beauty of this process is that we become your postdocs," reads one 2001 e-mail from a DesignWrite employee to an academic author. "We provide you with an outline that you review and suggest changes to. We then develop a draft from the final outline. You have complete editorial control of the paper but we provide you with the materials to review/critique."

More troubling, says Fugh-Berman, is that the ghostwritten articles downplayed the risk that HRT might promote breast cancer by disputing epidemiological data showing such a link.

At the same time the papers supported unvetted 'off-label' uses for HRT that were not approved by drug regulators, including healthier skin, protection against Alzheimer's and Parkinson's diseases, and a generally higher quality of life. Drug companies are not allowed to make such claims in their advertising. "They have to be channelled through the mouths of academics," says Fugh-Berman.

Ghostwritten articles also questioned other therapies and the effectiveness of generic hormone treatments, she says.

Author contributions

In a statement provided by spokesman Christopher Loder, Pfizer disputes Fugh-Berman's conclusions. "This article completely--and conveniently--ignores the fact that the published manuscripts were subjected to rigorous peer review by outside experts on behalf of the medical journals that published them."

The company also notes that it has clamped down on ghostwriting by requiring that academic authors are involved in papers throughout their writing, and that the contributions of authors who did not write the paper are explained.

"This behaviour has happened, but arguably not often, and probably not recently," says Thomas Stossel, director of the Translational Medicine Division at the Brigham and Women's Hospital in Boston, Massachusetts. Fugh-Berman's analysis conflates legitimate services offered by professional medical writers and ghostwriting, he says. "The fact is that such writers provide assistance to academics as well as commercial entities, just as speechwriters abet politicians."

But Leemon McHenry, a medical ethicist at California State University in Northridge who has investigated the use of ghostwriters on articles about other drugs, thinks that the practice stretches beyond these high-profile cases.

"How many other drugs have been promoted in the same way, but you never find out about them because nobody's suffered heart attacks?" he says. "Nobody finds out about this at all until there's been some major damage and the lawsuits get filed."


Nature

4 Comments

Add Comment
View
  1. 1. JamesDavis 07:54 AM 9/8/10

    I wonder how many women got breast cancer or a stroke from these HRT's and didn't say anything about it because of advice from their doctors or the doctors covered for the pharmaceutical industries. I know that some of the women where I live didn't say or do anything when they came down with breast cancer because they didn't know what to do or what to say and their OB-GYN told them that they were warned about the risks and they, the patient, decided that the benefits out weighed the risk and signed a paper saying that the doctor could not be sued for any side-effects the HRT could have.

    Are doctors told the truth about the dangerous side-effects of the drugs they give to people?

    Reply | Report Abuse | Link to this
  2. 2. jtdwyer 11:31 AM 9/8/10

    Do other scientific conglomerates such as NASA and CERN employ writers to 'assist' researchers in producing papers for scientific publications? I can imagine how this organized approach to producing publication of research could be beneficial in providing consistency of results and perhaps even provide support for corporate agendas such as public funding justification.

    Reply | Report Abuse | Link to this
  3. 3. scientific earthling 06:50 PM 9/8/10

    The homo sapien is a corrupt organism, the sooner extinct the better for the rest of the living creatures on this planet. Every aspect of homo sapien life is corrupt from the justice system to so called benevolent charity organisations.

    We were told governments by their nature are corrupt. Hence banking was entrusted to private organisations regulated by independent government bodies, we now know how they destroyed our monitory systems.

    We were told communism was evil and capitalism brought out the best in all of us. Is there any difference?

    In communism one group "the government" owns everything. In capitalism one group owns everything including the government.

    Lets hope the sixth extinction takes out the worst garbage on this planet, us.

    Reply | Report Abuse | Link to this
  4. 4. JamesDavis in reply to scientific earthling 08:59 PM 9/8/10

    I've never agreed with you before "scientific earthling", but this time I totally agree with every thing you said and especially the last sentence.

    Not all us humans are garbage, only the majority and they are in political offices of one kind or another.

    Reply | Report Abuse | Link to this
Leave this field empty

Add a Comment

You must sign in or register as a ScientificAmerican.com member to submit a comment.
Click one of the buttons below to register using an existing Social Account.

More from Scientific American

See what we're tweeting about

Scientific American Editors

More »

Free Newsletters


Get the best from Scientific American in your inbox

Solve Innovation Challenges

Powered By: Innocentive

  SA Digital
  SA Digital

Science Jobs of the Week

Email this Article

Questions over ghostwriting in drug industry

X
Scientific American Magazine

Subscribe Today

Save 66% off the cover price and get a free gift!

Learn More >>

X

Please Log In

Forgot: Password

X

Account Linking

Welcome, . Do you have an existing ScientificAmerican.com account?

Yes, please link my existing account with for quick, secure access.



Forgot Password?

No, I would like to create a new account with my profile information.

Create Account
X

Report Abuse

Are you sure?

X

Institutional Access

It has been identified that the institution you are trying to access this article from has institutional site license access to Scientific American on nature.com. To access this article in its entirety through site license access, click below.

Site license access
X

Error

X

Share this Article

X